On May 26, 2020, GenScript Biotech announced that it had obtained CE-IVD for its SARS-CoV-2 diagnostic products to be sold as an in vitro diagnostic.

Among these products was the novel cPassﾙ SARS-CoV-2 Neutralization Antibody Detection Kit, also known as SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit, which detects the presence of neutralizing antibodies in an hour and does not require live biological materials or biosafety containment for testing.